

SUBJECT INDEX TO VOLUME 3

- Acetylcholine 127
 in cardiovascular/pulmonary modulation 128
 in motor modulation 128
 in regulation of sleep 128
 in sensory modulation 128
 on cholinergic receptor 127
 on muscarinic receptor 127
 on nicotinic receptor 127
- Alcohol withdrawal 290
 glycine-B site NMDAR antagonists in 290
 NR2B subunit selective NMDAR antagonists in 290
- Alpha 2-adrenergic agonists 317
 and imidazoline receptor hypotheses 320
 effects on neurons/astrocytes 320
 in cerebral ischemia 317
 inhibition of adenylate/guanylate cyclases by 319
 inhibition of calcium channels by 319
 neuroprotection by 317
 pharmacology of 317
 protein-linked inward rectifying K⁺ channels by 319
- Antipsychotics 74
 treatment response to 74
- Axonal regeneration 260
 in spinal cord injury by M-Sch 260
- Bone marrow stromal cells 257
 application to muscle degeneration models 263
 application to Parkinson's disease 262
 application to stroke 261
 application for neurodegenerative disease 257
 for cell transplantation 262
 in muscle degenerative diseases 257
 in neuro-traumatic diseases 257
 induction of muscle-lineage cells from 262
 induction of neuronal cells from 261
 muscle repair by 262
- Caffeine 309
 basic neuropharmacological effects of 309
 effects on adenosine A1/A2A receptors 309
 effects on cortical synapses 309
 effects on GABA receptors 310
 effects on long-term depression 310
 effects on long-term potentiation 310
 effects on morphological changes in synapses 310
 effects on networks in brain 309
 effects on PDEs 310
 effects on postsynaptic sites 310
 effects on presynaptic sites 310
 effects on ryanodine receptors 310
 for functional modification 309
 neuropharmacological effects at cortical synapses 310
 neuropharmacological effects on cortico-cortical
 signal interactions 310
- Cannabinoid 129
- Cannabis pharmacotherapies 95,96
 abstinence symptoms treatment medication in 96
 detoxification in 95
 developing pharmacotherapies to 95
 maintenance phase for 95
 relapse prevention medication in 100
- CB1 receptor 53
 of endocannabinoid system 53
- Cerebral ischemia 318
 attenuation of excitatory transmitter release in 318
- Cholecystokinin 128
- Cholinergic system 64
 clinical/preclinical evidences of 64
 implication of 64
 in psychotic/cognitive symptoms 64
- Chronic opioid treatment 161
 neuroadaptation to 161
- CNS Mu opioid receptors 157
 adaptation of 157
 co-localization of 172
 determinants of region-specific adaptation of 171
 effect of chronic opioid agonist administration 157
 regional differences in 157
 role of GRK/ β -arrestin 169
 role of signaling proteins 172
 sensitization of 170
 target proteins of 169
- Cocaine pharmacotherapies 102
- Cocaine use disorders 95
 abstinence symptoms treatment medication in 102
 detoxification in 95
 developing pharmacotherapies for 95
 maintenance phase for 95
 relapse prevention medication in 103
- Cognitive dysfunction 45
 and pre-frontal cortex in schizophrenia 45
 GABA targets for treatment of 45
 in schizophrenia 45
- Cortical plasticity 151
 drugs in 151
 effects of modulating adrenergic
 neurotransmission in 151
 somatosensory skills in 151
 motor cortex excitability motor skills in 151
- Dopamine 125
 in motor modulation 126
 in sensory modulation 126
 receptor for 126
- Flavonoids 193,194
 bioavailability of 198
 controversial effects of 200

- effect on brain193
 hypothesis for201
 in brain *in vivo*198
 mechanisms of193
 mechanisms of protective actions *in vivo*201
 protective capacity of193
 structure of195
- GABA_A receptors50
 α₂subunit of50
- Gender differences75
 in pharmacokinetics of SGAs75
 in side effects of SGAs.....76
- Glutamate122
 cardiovascular-pulmonary modulation by124
 classification of agonists of.....122
 motor modulation by123
 receptor for122
 sensory modulation by123
- Glycine125
 in cardiovascular modulation.....125
 in modulation.....125
 in motor modulation.....125
 receptor for125
- Glycine transporter-1 inhibitors.....35
 as novel therapeutic target for treatment of
 schizophrenia.....35
- Glycine site modulators35
 as novel therapeutic target for treatment of
 schizophrenia.....35
- G-protein signaling (RGS) proteins165
- Group II mGlu receptors.....17
 as potential antipsychotic agents17
- Heart rate238
 elicited by 5-HT 3 receptor activation238
 inhibition of reflex control of238
- 5-HT₃ receptors231
 at NTS level237
 at ventral medullary level237
 in serotonin-mediated neural control of
 cardiovascular function231
 mechanisms underlying pressor response to237
 physiological role of240
 role of231
- Hypocretin (Orexin).....129
- Inhibitory amino acids124
 GABA as.....124
 in motor modulation125
 in pain modulation.....124
 receptor for124
- Intra-NTS microinjection235
 cardiovascular effects of235
- of 5-HT235
 of 5-HT receptor agonists/antagonists235
- Iptakalim hydrochloride (IPT)249
 blocks agonist-induced Ca²⁺ release from
 intracellular Ca²⁺ stores253
 directly blocks neuronal ionotropic glutamate
 receptors253
 in neuronal protection249
 protects cells against neurodegeneration by acting
 on other central targets253
 protects cells against neurodegeneration in
 parkinson's disease (PD) animal models251
 protects cells against neurodegeneration in *in vitro*
 ischemic animal models250
 protects cells against neurodegeneration in
 in vitro PD animal models251
 protects cells against neurodegeneration in
 in vivo ischemic animal models249
 protects cells against neurodegeneration in
 in vivo PD animal models251
 protects cells against neurodegeneration through
 opening of cytoplasmic K_{ATP} channels251
 protects cells against neurodegeneration through
 opening of K_{ATP} channels251
 protects cells against neurodegeneration through
 opening of mitochondrial K_{ATP} channels253
 protects cells against neurodegeneration in
 ischemic models249
- Learning146
 biochemical mechanisms of146
 effects of drugs147,151
 effects of modulating adrenergic
 neurotransmission in.....151
 motor cortex excitability motor skills in151
 somatosensory skills in.....151
- Medial medulla.....115
 sensory-motor integration in115
 electrophysiological studies of.....117
 in modulation of sensory-motor activity.....117
- Metabotropic glutamate receptor9,14,299
 agonists of299
 agonists/antagonists as candidate drugs to
 prevent epileptogenesis300
 antagonists of299
 as anticonvulsants299
 as antiepileptogenic299
 function of.....9
 in animal model of seizures299
 in both animal/human temporal lobe epilepsy299
 in status epilepticus299
 in vivo studies of300
 modulation of.....9
- MGLu5 receptor activators14
 antipsychotic efficacy of15
 for regulating NMDA receptor function.....14

MGlu5 receptor ligands	15	sensitization of	170
behavioral effects of	15	splice variants of	171
MGlu5 receptors	15	Muscarinic receptors	53,63
allosteric potentiators of	15	of acetylcholine system	53
as potential antipsychotic agents	15	selective targeting of	63
Motor cortex excitability	147	Muscarinic 1 receptors	65
effects of modulating dopaminergic		and schizophrenia	65
neurotransmission on	153	Muscarinic 2 receptors	66
effects of modulating glutamatergic synaptic		and schizophrenia	66
transmission on	147	Muscarinic 4 receptors	67
effects of modulating serotonergic		and schizophrenia	67
neurotransmission on	152	Muscarinic 5 receptors	67
effects of NMDA receptor antagonists on	147	and schizophrenia	67
Motor skills	147	Neurodegenerative diseases	260
effects of NMDA receptor antagonists	149	cell transplantation in	260
effects of modulating adrenergic		Neuronal Cl ⁻ channels	207
neurotransmission on	151	and bestrophins	209
effects of GABA _A receptor agonists on	149	and pH	211
effects of modulating cholinergic		and transporters	209
neurotransmission on	149	and YFP	213
effects of modulating dopaminergic		automated patch-clamp electrophysiology of	210
neurotransmission on	153	Ca ²⁺ -activated Cl ⁻ channels as	209
effects of modulating serotonergic		CLC Cl ⁻ channel family of	207
neurotransmission on	152	colorimetry of	211
Motor/somatosensory skills	145	cysteine-loop Cl ⁻ channel family of	208
in humans	145	families of	207
pharmacology of	145	GABAAR as	208
MSC-derived schwann (M-Sch) cells	259	GABACR as	208
M-Sch transplantation	259	GlyR as	208
PNS regeneration by	259	high-throughput screening of	207
Mu opioid receptors (MOR)	157	HTS techniques for	210
and calmodulin-dependent protein kinase		invertebrate ligand-gated anion channels as	209
(CaMK)	168	of unknown molecular identity	209
and intracellular kinases	167	other types of	209
and MAPK	169	radioactive assays of	210
and oligomers	171	swelling-activated Cl ⁻ channels as	210
and protein kinases C (PKC)	167	Neuroplasticity	217
autonomic/neuroendocrine function of	159	cholinergic modulation of	224
co-localization of	172	effects of ion channel-modulation on	225
desensitization of	163	gabaergic influences on	220
determinants of region-specific adaptation of	171	in humans	217
effect of antinociception	159	modulation of	217
effect of G-proteins	163	monoaminergic modulation of	223
effect of RGS proteins	165	NMDA receptor-dependency of	218
effect on adenylyl cyclase	166	pharmacological characterization of	217
functional neuronatomy of	158	Neurotensin	128
in signaling	160	NGC/NMC neuron	116
in withdrawal	159	anatomical link between	116
internalization of	162	and cranial sensory	116
levels of	162	and motor nuclei	116
localization of	158	and spinal cord	116
reinforcement by	159	cardiovascular/respiratory activities of	119
role of chronic opioid treatment	161	in amyotrophic lateral sclerosis	130
role of GRK/ β -arrestin	169	in brainstem	116
role of ion channels	167	in cerebellum	116
role of signaling proteins	172		

in forebrain	116	receptors for	120
in modulation of sensory activity	118	sensory modulation by	121
in motor activity	118	Oxidative stress	194
in narcolepsy/cataplexy	130	effect on brain	194
in neurodegenerative diseases	129	Partial dopamine agonists	3
in neurological diseases	129	in schizophrenia	5
in neuronal response to sensory stimuli	116	in treatment of psychosis	3
in other neurological diseases	130	mechanisms of	4
in Parkinson's disease (PD)	129	testing of	5
in periodic leg movement disorder	130	Prefrontal parvalbumin neurons	50
in REM sleep behavior disorder (RBD)	130	as pharmacological targets	50
in sleep	119	function of	50
motor modulation by	122	in schizophrenia	50
pharmacological characterization of	120	Psychosis	3
phenotypes of	116	aripiprazole in	6
sensory modulation by	123	new partial dopamine agonists in	6
somatic/viseral outputs of	119	Psychotic disorders	63
NGC/NMC-serotonin system	127	novel therapeutic approaches for	63
physiological functions of	127	Putative neuronal Cl ⁻ channels	209
NMDA receptors	281	Rosetromedial medulla	115
and ethanol	282	terminology of	115
consequences of changes in structure of	286	Schizophrenia	9,35,45,74
consequences of increased function of	286	alterations in subset of prefrontal cortical	
effect of long-term ethanol exposure on		GABA neurons in	46
functions of	284	DAAO/serine role of racemase/D-serine	
effect of long-term ethanol exposure on		transporter(ASC-1)	39
structure of	285	D-serine approaches towards	39
ethanol as inhibitor of	284	gender differences in course of	74
functions of	281,283	glutamate/NMDA hypofunction hypothesis of	10
in development of alcohol dependence	281	novel potential therapeutics for	9
role of altered structure of	281	role of glycine transporter blockade in	37
structure of	283	role of glycine site activators in	36
NMDAR antagonists	288	role of serotonin receptors	51
acamprosate as	288	Schizophrenic brain	20
competitive/channel blocking by	289	group I mGlu/group II mGlu receptors gene	
in pharmacotherapy of alcohol withdrawal	288	expression in	20
Norepinephrine	126	Schwann cell	258
adrenergic receptor of	126	in axonal regeneration	258
effect on α -adrenergic receptor	126	induction from MSCs	258
effect on β -adrenergic receptor	127	Second generation antipsychotic drugs	73
in motor modulation	127	cardiac side effects of	76
in pain modulation	127	extrapyramidal symptoms of	79
Nucleus tractus solitarius	232	gender differences in	73
effect of excitatory amino acids	234	hyperprolactinemia by	77
effect of GABA	234	pharmacokinetics of	73
effect of serotonin	234	sexual side effects of	77
effect of substance P	234	side effects of	73
efferents involved in baroreceptor reflex arc	232	weight gain by	78
peripheral/central afferents from	232	Sensorimotor system	150
respective receptors involved in cardiovascular		effects of GABA _A receptor agonists	150
control in	233	effect of NMDA receptor	150
role of neurotransmitters	233	interconnectedness in	150
Opioids	120		
classification of agonists of	120		
motor modulation by	122		

Sensory system.....	117	in body	270
Serotonin.....	127	in lipid transport	275
receptor for	127	in membrane remodeling	275
Sigma ligands	268	knockout mouse of	277
Sigma receptor	267	role in cellular differentiation	276
gene for	267	role in myelination	276
in neuropsychopharmacology	267	up-/down-regulation in <i>in vivo</i>	275
structure of	268	upregulation in <i>in vitro</i>	275
translocation of	274	upregulation on cellular functions	275
Sigma-1 receptors	270	Sigma-1 receptor ligands	272
behavioral roles of	276	acute action of.....	272
brain distribution of	270	channel regulation by	272
cellular biological/physiological roles of	272	effect on cellular functions	272
cellular distribution of	270	Somatosensory skills.....	147
chronic action of	275	effects of GABA _A receptor agonists	147
distribution of	270	effect of NMDA receptor antagonists.....	147
human study of	278	Substance P.....	128